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Despite several critical steps forward in the management of chronic
heart failure (CHF), the area of acute heart failure (AHF) has
remained relatively stagnant. As stated in the updated ESC HF guide-
lines, clinicians responsible for managing patients with AHF must
frequently make treatment decisions without adequate evidence,
usually on the basis of expert opinion consensus.2 Specifically, the
treatment of acute HF remains largely opinion-based with little
good evidence to guide therapy.
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Acute heart failure is a syndrome in which emergency physicians,
cardiologists, intensivists, nurses, and other healthcare providers
have to cooperate to provide ‘rapid’ benefit to the patients. We
hereby would like tounderscore thewiderexperiencegrown indiffer-
ent settings of the area of intensive care on acute heart failure, actually
largerand more composite than that got in specialized Care Units.The
distillateof suchdifferentexperiences isdiscussedand integrated in the
presentdocument.Hence, the authorsof this consensus paperbelieve
a common working definition of AHF covering all dimensions and
modes of presentations has to be made, with the understanding that
most AHF presentations are either acute decompensations of
chronic underlying HF or the abrupt onset of dyspnoea associated
with significantly elevated blood pressure. Secondly, recent data
show that, much like acute coronary syndrome, AHF might have a
‘time to therapy’ concept. Accordingly, ‘pre-hospital’ management is
considered a critical component of care. Thirdly, most patients with
AHF have normal or high blood pressure at presentation, and are
admitted with symptoms and/or signs of congestion. This is in contra-
diction to the presentation where low cardiac output leads to symp-
tomatic hypotension and signs/symptoms of hypoperfusion, a
circumstance that is relatively rare, present in coronary care unit/
intensive care unit (CCU/ICU) but associated with a particularly
poor outcome. Hence, it is important to note that appropriate
therapy requires appropriate identificationof the specific AHF pheno-
type.3 The aim of the current paper is not to replace guidelines, but, to
provide contemporary perspective for early hospital management
within the context of the most recent data and to provide guidance,
based on expert opinions, to practicing physicians and other health-
care professionals (Figure 1). We believe that the experience
accrued in the different settings from the emergency department
through to the ICU/CCU is collectivel valuable in determining how
best to manage the patients with AHF. Herein, a shortened version
mainly including group recommendations is provided. Full version of
the consensus paper is provided as Supplementary material online.
Figure 1 Algorithm for the management of acute heart failure. AHF, acute heart failure; VAS, Visual Analogue Scale for dyspnea assessment; RR,
respiration rate; SpO2, blood oxygen saturation; HR, heart rate; ICU, intensive care unit; Cathlab, cardiac catheterisation laboratory; CCU, coronary
care unit; IV, intravenous; SBP, systolic blood pressure; cTn, cardiac troponin, th, therapy, ACS, acute coronary syndrome.
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Definition and epidemiology
of acute heart failure
† Acute heart failure (AHF) is the term used to describe the rapid
onset of or acute worsening of symptoms and signs of HF, asso-
ciated with elevated plasma levels of natriuretic peptides. It is a life-
threatening condition that requires immediate medical attention
and usually leads to urgent hospital admission.
† Most of the patients with AHF present with normal or high blood
pressure and with symptoms and/or signs of congestion rather
than low cardiac output.
Table 1 compares the characteristics among patients whose initial
management was performed in cardiology/CCU, emergency depart-
ment (ED), or pre-hospital setting. Clinical characteristics are
somewhat different; AHF patients seen early, in the pre-hospital
setting or in the ED not only have higher blood pressure but also
are more frequently female and older.4
Pre-hospital and early
management strategies in
acute heart failure
† As for acute coronary syndromes, the ‘time-to-treatment’
concept may be important in patients with AHF. Hence, all AHF
patients should receive appropriate therapy as early as possible.
† In the pre-hospital setting, AHF patients should benefit from:
– Non-invasive monitoring, including pulse oximetry, blood
pressure, respiratory rate, and a continuous ECG, instituted
within minutes of patient contact and in the ambulance if
possible.
– Oxygen therapy given based on clinical judgment unless
oxygen saturation ,90% in which case oxygen therapy should
be routinely administered.
– Non-invasive ventilation, in patients with respiratory
distress.
Figure 1 Continued.
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– Medical treatment should be initiated based on blood pressure
and/or the degree of congestion using vasodilators and/or
diuretics (i.e. furosemide).
– Rapid transfer to the nearest hospital, preferably to a site with
a cardiology department and/or CCU/ICU.
† On arrival in the ED/CCU/ICU, initial clinical examination, in-
vestigations and treatment should be started immediately and
concomitantly.
Initial clinical evaluation and
investigations at arrival in the
emergency department/coronary
care unit/intensive care unit
† In the initial evaluation of suspected AHF (excluding cardiogenic
shock), the critical first step is determination of the severity of car-
diopulmonary instability based on the level of dyspnoea, haemo-
dynamic status, and heart rhythm. To facilitate this, results of the
following assessments should be recorded (Figure 1):
– Objective measurement of dyspnoea severity, including the re-
spiratory rate, intolerance of the supine position, effort of
breathing, and degree of hypoxia.
– Systolic and diastolic blood pressure.
– Heart rate and rhythm.
– Objective determination of body temperature and signs/symp-
toms of hypoperfusion (cool extremities, narrow pulse pres-
sure, mental status)
† The next stepshould includea search forcongestion includingper-
ipheral oedema, audible rales (especially in the absence of fever),
and elevated jugular venous pressure,
† Additional testing that may be useful includes:
– ECG, recognizing that in AHF this is rarely normal, and rarely
diagnostic but necessary to exclude ST segment elevation myo-
cardial infarction
– Laboratory tests (see below)
– Bedside thoracic ultrasound for signs of interstitial oedema
(Figure 2) and abdominal ultrasound for inferior vena cava diam-
eter (and ascites) if expertise is available
Figure 2 (A and B) Thoracic ultrasound images in normal and AHF
patients. (A) From the pleural line, one repetition of the pleural line, a
horizontal line [A line], parallel to the pleural line, is visible, indicating
normal lungwithno pulmonaryoedema.Note some ill-definedvertical
comet-tail artefacts, not to be confused with lung rockets. Arrows indi-
cate A lines. (B) Fouror five B-lines arise from the pleural line, creating a
pattern called lung rockets. B lines are vertical, long, well-defined arte-
facts erasing the A-lines and moving in concert with lung sliding. B lines
indicatepulmonaryoedema.FromWholeBodyUltrasonography inthe
Critically Ill, Springer 2010 (with kind permission of Springer Science).
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Table 1 Clinical characteristics of the AHF patients according to the different sites of initial contact and management
Admission site Cardiac ICU/CCU Emergency department Pre-hospital setting
Euro-HF II
n5 3580
EFICA
n 5 599
ADHERE
n 5 159 168
ATTEND
n 5 1100
Ducros et al.
n5 207
Sporer et al.
n 5 319
Male (%) 61 59 49 59 41 47
Age (years) 70 73 73 72 81 77
SBP. 140 mmHg at admission (%) 63 60 74 71 75 77
CS or SBP, 90 mmHg (%) 3.9 29 3 NA 1 3
Initial SBP 135 126 144 147 170 167
Of note, EFICA includes only ICU patients.
Euro-HF II,8 EFICA,9 ADHERE,10 ATTEND,11 Ducros et al.,12 Sporer et al.13
SBP, systolic blood pressure; ICU, intensive care unit; CCU, coronary care unit; CS, cardiogenic shock.
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– Chest X-ray to rule-out alternative causes of dyspnoea, though, in
nearly20%ofpatients, itmaybenormal, limitingoverall sensitivity.
† Immediateechocardiography is notneededduring the initial evalu-
ation in most cases except when haemodynamic instability is
present. However, echocardiography is needed after stabilization,
especially with de novo disease.
† Urinary catheterization should be avoided unless the benefits out-
weigh the risks of infection and longer term complications related
to continence.
Laboratory tests at presentation
† Upon presentation to the ED or CCU/ICU, a plasma natriuretic
peptide level (BNP, NT-proBNP, or MR-proANP) should be mea-
sured in all patients with acute dyspnoea and suspected AHF,
ideally using a point-of-care assay, to help in the differentiation
of AHF from non-cardiac causes of acute dyspnoea.
† The following laboratory assessments should be performed at ad-
mission in the blood of all AHF patients: troponin, BUN (or urea),
creatinine, electrolytes, glucose and complete blood count.
† D-dimer is indicated in patients with suspicion of acute pulmonary
embolism.
† Routine arterial blood gas is not needed. However, arterial blood
gas may be useful when a precise measurement of oxygen and
carbon dioxide partial pressures is needed. Venous sample
might acceptably indicate pH and CO2.
Role of nursing management
in acute heart failure
† Specific considerations of nursing management include:
– Triage to appropriate environment for safe clinical care
– Objective monitoring for change in signs and symptoms sug-
gestive of response to treatment.
– Discharge planning and referral to multidisciplinary disease
management programme.
† Anxiety of the patient should be addressed by promptly answering
questions andprovidingclear information to the patient and family.
† Relevant changes in clinical status should be promptly addressed
and communicated to the physician. Effective and consistent com-
munication should be maintained with the patient and/or family
Oxygen therapy and/or ventilatory
support
† Oxygenation should be monitored with pulse-oximetry (SpO2)
(Figure 3)
† Acid-base balance, complementing SpO2 monitoring, should be
obtained onadmission, especially inpatientswith acutepulmonary
oedema (APE) or previous historyof chronic obstructive pulmon-
ary disease, using venous blood or especially in patients with
cardiogenic shock through the arterial line
Figure 3 Oxygen and ventilatory support in acute heart failure. PS-PEEP, pressure support-positive end-expiratory pressure. CPAP, continuous
positive airway pressure; RR, respiration rate; SpO2, oxygen saturation.
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† Oxygen therapy should be considered in patients with AHF having
SpO2, 90%
† Non-invasive ventilation (NIV) is indicated in patients with
respiratory distress and should be started as soon as possible.
Non-invasive ventilation decreases respiratory distress and also
reduces the rate of mechanical endotracheal intubation
Early administration of intravenous
diuretics and vasodilators
† Initially, 20–40 mg intravenous furosemide can be considered in
all AHF patients
† In cases of volume overload, intravenous diuretic dose should be
tailored to the type of AHF (de novo with lower dose than exacer-
bation of CHF, Table 2).
† When systolic BP is normal to high (.110 mmHg),2 intraven-
ous vasodilator therapy, might be given for symptomatic relief
as an initial therapy. Alternatively, sublingual nitrates may be
considered.
Drugs to be used cautiously in acute
heart failure (excluding cardiogenic
shock)
† Routine use of opioids in AHF patients is not recommended
† There is only a very limited place for sympathomimetics or
vasopressors in patients with AHF excluding cardiogenic
shock; they should be reserved for patients who have persistent
signs of hypoperfusion despite adequate filling status.
Management of evidence-based
oral therapies
† In case of decompensation of CHF, every attempt should be made
to continue evidence-based, disease-modifying, oral therapies in
patients with AHF (Table 3).
† In the case of de novo HF, every attempt should be made to initiate
these therapies after hemodynamic stabilization.
Discharge from emergency
department
† Clinical conditioncan changedramatically within a fewhoursof ED
arrival. Hence, clinical response to initial treatment is an important
indicator of likely disposition.
† Indicators of good response to initial therapy that might be consid-
ered in discharge include:
– Patient-reported subjective improvement
– Resting HR, 100 bpm
– No hypotension when standing up
– Adequate urine output
– Oxygen saturation . 95% in room air
– No or moderate worsening of renal function (chronic renal
disease might be present)
† Fast track discharge from ED should be considered in hospitals
with chronic disease management programs, once the trigger
for decompensation has been identified and early management
commenced
† Patients withde novoAHF should not be dischargedhome fromED
Criteria forhospitalization inwardvs.
intensive care unit/coronary care unit
† Patients with significant dyspnoea or haemodynamic instability
should be triaged to a location where immediate resuscitative
support can be provided if needed.
† Patients admitted to hospital with AHF should be looked after by
doctors and nurses with specialist knowledge and expertise
† For high-risk patients, initial care should be provided in a high depend-
ency setting (Coronary Care/Cardiac Care Unit). Patients with AHF
and associated acute coronary syndrome should be referred to CCU.
– Clinical risk algorithms developed topredict the in-hospitalmor-
tality of patients admitted with AHF can assist in determining
which patients in the ED need the highest level of in-patient care
– An ED specific algorithm may further improve risk assessment
compared with prior methods developed in patients admitted
with AHF
– The criteria for triage at admission for ICU include RR. 25,
SaO2, 90%, use of accessory muscles for breathing, systolic
BP, 90 mmHg,
– Need for intubation (or already intubated) or signs of hypo-
perfusion: (oliguria, cold peripheries, altered mental status,
lactate .2 mmol/L, metabolic acidosis, SvO2 , 65%) are
also indications for ICU referral
† For those who are admitted to the ICU/CCU, subsequent care
should be on a cardiology ward if possible
† Hospitals should have an AHF pathway so all patients have access
to cardiology advice.
Monitoring in the hospital
† Patient should be weighed daily and have an accurate fluid balance
chart completed
† Standard non-invasive monitoring of pulse, respiratory rate, and
blood pressure should be performed
† Renal function and electrolytes should be measured daily
† Pre-discharge measurement of natriuretic peptides is useful for
post-discharge planning
Table 2 Dose recommendations for diuretic therapy
New-onset HF or no maintenance
diuretic therapy
Furosemide 40 mg intravenous
HF on chronic oral therapy Furosemide iv bolus at least
equivalent to oral dose
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Criteria for discharge from the
hospital and follow-up in
high-risk period
† Patients admitted with AHF are medically fit for discharge:
– when haemodynamically stable, euvolemic, established on
evidence-based oral medication and with stable renal function
for at least 24 h before discharge
– once provided with tailored education and advice about
self-care
† Patients should be:
– enrolled in a disease management program
– seen by their general practitioner within 1 week of discharge
– seen by the hospital cardiology team within 2 weeks of dis-
charge if feasible
† Patients with chronic heart failure should be followed up within
a multi-professional heart failure service
Definition, initial management
and monitoring of cardiogenic
shock including device therapy
† Cardiogenic shock is defined as hypotension (SBP, 90 mmHg)
despite adequate filling status and signs of hypoperfusion: (oliguria,
cold peripheries, altered mental status, lactate.2 mmol/L, meta-
bolic acidosis, SvO2, 65%)
† A patient with suspected cardiogenic shock (CS) should undergo
immediate assessment
† ECG and echocardiography are required immediately in all
patients with suspected CS
† Invasive monitoring with arterial line is needed
† There is no agreement on optimal method of haemodynamic
monitoring in assessing and treating the patient in CS, including
pulmonary artery catheter
† Fluid challenge (saline or ringer lactate, .200 mL/15–30 min) is
recommended as the first line treatment if there is no sign of
overt fluid overload
† Dobutamine may be used to increase cardiac output; levosimen-
dan may be considered, especially in CHF patients on oral beta-
blockade
† Vasopressors should only be used if there is a strict need to
maintain systolic BP in the presence of persistent hypoper-
fusion; if needed, norepinephrine is recommended over
dopamine
† All CS should be rapidly transferred to a tertiary care centre
which has a 24/7 service of cardiac catheterization, and a
dedicated ICU with availability of short-term mechanical circula-
tory support
† Intraaortic ballon pump is not routinely recommended in CS
† Short-term mechanical circulatory support may be considered in
refractory CS depending on patient age, comorbidities and neuro-
logical function
† Based on current evidence, we do not recommend one mode of
short-term circulatory support over another
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Gaps in knowledge and
perspectives
In AHF, there are several areas which require further investigation.
The use of biomarkers in risk stratification and to guide treatment,
which are the most important signs of severity, and which are the
best measures of efficacy need more extensive study. There is still
a need to better delineate exactly what constitutes clinical improve-
ment with acute therapy, types of rehospitalizations, and mortality
(both short-term and long-term). There is also an appealing concept
of ‘home visit’ by ‘HF-teams’ to avoid or to decrease ED visits and
hospitalizations.
Recent phase III or IV investigations have offered future promise in
clinical management of Acute Heart Failure. These include RELAX-
AHF5 (serelaxin), ATOMIC-AHF trial6 (omecamtiv mecarbil),
PRONTO7 (clevidipine), TRUE-AHF14 (clinicaltrials.gov/ct2/show/
NCT01661634?term=TRUE-AHF&rank=1), (clinicaltrials.gov/ct2/
show/NCT01733134) ARTS-HF15 trials.
Supplementary material
Supplementary material is available at European Heart Journal online.
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